Clinical and endoscopic evaluantion of gastroesophageal reflux disease in patients successfully treated with esomeprazole

Detalhes bibliográficos
Autor(a) principal: Silva,Edson Pedro da
Data de Publicação: 2003
Outros Autores: Nader,Farid, Quilici,Flavio A., Eisig,Jaime Natan, Zaterka,Schlioma, Meneghelli,Ulysses
Tipo de documento: Artigo (review)
Idioma: eng
Título da fonte: Arquivos de gastroenterologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032003000400012
Resumo: BACKGROUND: Esomeprazole, an S-isomer of omeprazole, is the first proton pump inhibitor developed as an optical isomer, and it has shown high healing rates in erosive esophagitis. AIM: To evaluate the efficacy and tolerability of esomeprazole in subjects with erosive esophagitis, according to the Los Angeles classification study design: an open, multi-center clinical study. MATERIAL AND METHODS: Two hundred and eighteen subjects with reflux esophagitis confirmed by endoscopy were included in an open, multi-center study in Brazil. All of them received esomeprazole 40 mg, once daily, for a 4-week period. Subjects who had unhealed esophagitis by week 4 continued the treatment for another 4 weeks. The primary efficacy endpoint was the healing rates by weeks 4 and 8. The secondary endpoints were the number of patients with symptom resolution by week 4, the number of days to sustained symptom resolution, number of symptom-free days and nights and safety and tolerability of the drug. RESULTS: Healing rates by weeks 4 and 8 were 82% (confidence interval: 77.4%-87.6%) and 96.1% (confidence interval: 93.5% - 98.8%), respectively. Ninety-nine (99%) of the patients had heartburn resolution by week 2. The most common adverse events were headache (4%), diarrhea (2.6%) and epigastric pain (2.2%). CONCLUSION: For the studied period, esomeprazole was shown to be a safe and well-tolerated drug, providing significant healing rates of mucosal breaks, regardless of LA classification, in patients with erosive esophagitis. Esomeprazole was also shown to be effective in quickly relieving symptoms.
id IBEPEGE-1_27eda9d448e226403fc84d2bdcaeaff1
oai_identifier_str oai:scielo:S0004-28032003000400012
network_acronym_str IBEPEGE-1
network_name_str Arquivos de gastroenterologia (Online)
repository_id_str
spelling Clinical and endoscopic evaluantion of gastroesophageal reflux disease in patients successfully treated with esomeprazoleGastroesophageal refluxEsophagitis, pepticHeartburnProton pumpsEsomeprazoleBACKGROUND: Esomeprazole, an S-isomer of omeprazole, is the first proton pump inhibitor developed as an optical isomer, and it has shown high healing rates in erosive esophagitis. AIM: To evaluate the efficacy and tolerability of esomeprazole in subjects with erosive esophagitis, according to the Los Angeles classification study design: an open, multi-center clinical study. MATERIAL AND METHODS: Two hundred and eighteen subjects with reflux esophagitis confirmed by endoscopy were included in an open, multi-center study in Brazil. All of them received esomeprazole 40 mg, once daily, for a 4-week period. Subjects who had unhealed esophagitis by week 4 continued the treatment for another 4 weeks. The primary efficacy endpoint was the healing rates by weeks 4 and 8. The secondary endpoints were the number of patients with symptom resolution by week 4, the number of days to sustained symptom resolution, number of symptom-free days and nights and safety and tolerability of the drug. RESULTS: Healing rates by weeks 4 and 8 were 82% (confidence interval: 77.4%-87.6%) and 96.1% (confidence interval: 93.5% - 98.8%), respectively. Ninety-nine (99%) of the patients had heartburn resolution by week 2. The most common adverse events were headache (4%), diarrhea (2.6%) and epigastric pain (2.2%). CONCLUSION: For the studied period, esomeprazole was shown to be a safe and well-tolerated drug, providing significant healing rates of mucosal breaks, regardless of LA classification, in patients with erosive esophagitis. Esomeprazole was also shown to be effective in quickly relieving symptoms.Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia e Outras Especialidades - IBEPEGE. 2003-12-01info:eu-repo/semantics/reviewinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032003000400012Arquivos de Gastroenterologia v.40 n.4 2003reponame:Arquivos de gastroenterologia (Online)instname:Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologiainstacron:IBEPEGE10.1590/S0004-28032003000400012info:eu-repo/semantics/openAccessSilva,Edson Pedro daNader,FaridQuilici,Flavio A.Eisig,Jaime NatanZaterka,SchliomaMeneghelli,Ulysseseng2004-05-31T00:00:00Zoai:scielo:S0004-28032003000400012Revistahttp://www.scielo.br/aghttps://old.scielo.br/oai/scielo-oai.php||secretariaarqgastr@hospitaligesp.com.br1678-42190004-2803opendoar:2004-05-31T00:00Arquivos de gastroenterologia (Online) - Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologiafalse
dc.title.none.fl_str_mv Clinical and endoscopic evaluantion of gastroesophageal reflux disease in patients successfully treated with esomeprazole
title Clinical and endoscopic evaluantion of gastroesophageal reflux disease in patients successfully treated with esomeprazole
spellingShingle Clinical and endoscopic evaluantion of gastroesophageal reflux disease in patients successfully treated with esomeprazole
Silva,Edson Pedro da
Gastroesophageal reflux
Esophagitis, peptic
Heartburn
Proton pumps
Esomeprazole
title_short Clinical and endoscopic evaluantion of gastroesophageal reflux disease in patients successfully treated with esomeprazole
title_full Clinical and endoscopic evaluantion of gastroesophageal reflux disease in patients successfully treated with esomeprazole
title_fullStr Clinical and endoscopic evaluantion of gastroesophageal reflux disease in patients successfully treated with esomeprazole
title_full_unstemmed Clinical and endoscopic evaluantion of gastroesophageal reflux disease in patients successfully treated with esomeprazole
title_sort Clinical and endoscopic evaluantion of gastroesophageal reflux disease in patients successfully treated with esomeprazole
author Silva,Edson Pedro da
author_facet Silva,Edson Pedro da
Nader,Farid
Quilici,Flavio A.
Eisig,Jaime Natan
Zaterka,Schlioma
Meneghelli,Ulysses
author_role author
author2 Nader,Farid
Quilici,Flavio A.
Eisig,Jaime Natan
Zaterka,Schlioma
Meneghelli,Ulysses
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Silva,Edson Pedro da
Nader,Farid
Quilici,Flavio A.
Eisig,Jaime Natan
Zaterka,Schlioma
Meneghelli,Ulysses
dc.subject.por.fl_str_mv Gastroesophageal reflux
Esophagitis, peptic
Heartburn
Proton pumps
Esomeprazole
topic Gastroesophageal reflux
Esophagitis, peptic
Heartburn
Proton pumps
Esomeprazole
description BACKGROUND: Esomeprazole, an S-isomer of omeprazole, is the first proton pump inhibitor developed as an optical isomer, and it has shown high healing rates in erosive esophagitis. AIM: To evaluate the efficacy and tolerability of esomeprazole in subjects with erosive esophagitis, according to the Los Angeles classification study design: an open, multi-center clinical study. MATERIAL AND METHODS: Two hundred and eighteen subjects with reflux esophagitis confirmed by endoscopy were included in an open, multi-center study in Brazil. All of them received esomeprazole 40 mg, once daily, for a 4-week period. Subjects who had unhealed esophagitis by week 4 continued the treatment for another 4 weeks. The primary efficacy endpoint was the healing rates by weeks 4 and 8. The secondary endpoints were the number of patients with symptom resolution by week 4, the number of days to sustained symptom resolution, number of symptom-free days and nights and safety and tolerability of the drug. RESULTS: Healing rates by weeks 4 and 8 were 82% (confidence interval: 77.4%-87.6%) and 96.1% (confidence interval: 93.5% - 98.8%), respectively. Ninety-nine (99%) of the patients had heartburn resolution by week 2. The most common adverse events were headache (4%), diarrhea (2.6%) and epigastric pain (2.2%). CONCLUSION: For the studied period, esomeprazole was shown to be a safe and well-tolerated drug, providing significant healing rates of mucosal breaks, regardless of LA classification, in patients with erosive esophagitis. Esomeprazole was also shown to be effective in quickly relieving symptoms.
publishDate 2003
dc.date.none.fl_str_mv 2003-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/review
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format review
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032003000400012
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032003000400012
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0004-28032003000400012
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia e Outras Especialidades - IBEPEGE.
publisher.none.fl_str_mv Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia e Outras Especialidades - IBEPEGE.
dc.source.none.fl_str_mv Arquivos de Gastroenterologia v.40 n.4 2003
reponame:Arquivos de gastroenterologia (Online)
instname:Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia
instacron:IBEPEGE
instname_str Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia
instacron_str IBEPEGE
institution IBEPEGE
reponame_str Arquivos de gastroenterologia (Online)
collection Arquivos de gastroenterologia (Online)
repository.name.fl_str_mv Arquivos de gastroenterologia (Online) - Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia
repository.mail.fl_str_mv ||secretariaarqgastr@hospitaligesp.com.br
_version_ 1754193342995890176